sacituzumab govitecan-hziy
Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.
Gilead has high hopes that anito-cel, a multiple myeloma cell therapy it is developing with Arcellx, can bolster its cell therapy franchise.
Gilead Optimistic About 11 Percent Q2 Growth in Cell Therapy Sales but Readying for Competition
Premium
The firm is working with providers to expand the use of Yescarta and Tecartus as competition from other CAR T-cell therapies and bispecifics heats up.
The firm is encouraged by the MAT2A inhibitor's commercial prospects after seeing its efficacy as a monotherapy in some MTAP-null bladder and lung cancer patients.
Ideaya Begins Testing MAT2A Inhibitor, Trodelvy in Phase I MTAP-Deleted Bladder Cancer Study
The firm will also begin studying the activity of IDE397 monotherapy in the same indication in a Phase II expansion cohort.
Aug 4, 2023
Apr 28, 2023
Gilead Q1 Oncology Segment Sales Jump 59 Percent
Feb 3, 2023
Oct 28, 2022
Sep 29, 2022
Apr 29, 2022